#1-Billion-Milestones

2 stories

Industry September 4, 2026 · View digest

Medicus Pharma and Pfizer Sign $12M Upfront, Up to $1B Milestone License for CD228-Targeting Antibody-Drug Conjugate PF-08046031

Medicus Pharma (NASDAQ: MDCX) announced Wednesday September 2, 2026 a Co-Development and License Agreement with Pfizer (NYSE: PFE) granting Medicus an exclusive, sublicensable, royalty-bearing worldwide license to develop, manufacture, and commercialize PF-08046031 (CD228V, an early clinical-stage antibody-drug conjugate targeting melanotransferrin / CD228). Terms: $12 million upfront cash to Pfizer, an additional $15 million payable on the first anniversary of the effective date, plus up to $1 billion+ in aggregate milestone payments and low-double-digit tiered royalties on future net sales. Pfizer paid Medicus $2 million in development funding restricted to the CD228V program. Medicus retains sole authority and control of development, manufacture, regulatory approval, and commercialization; Pfizer holds review-and-comment rights on development plans and an option to fund development from the first registrational trial. PF-08046031 originated in the Seagen pipeline acquired by Pfizer in December 2023 and represents one of several Seagen-descended assets Pfizer has out-licensed since the acquisition.

Industry August 28, 2026 · View digest

DualityBio and Genentech Sign $45 Million Upfront, $1 Billion+ Milestone ADC Deal on DUPAC Novel-Payload Platform Targeting TOPO1 Resistance

DualityBio (HKEX: 9606) announced Friday August 28, 2026 a global collaboration and license agreement with Genentech (Roche Group) to develop next-generation antibody-drug conjugates on DualityBio's proprietary DUPAC (DualityBio Unique Payload Antibody Conjugate) platform. Terms: $45 million upfront to DualityBio plus more than $1 billion in aggregate development, regulatory, and commercial milestone payments across all programs, with tiered royalties on annual net sales. DualityBio handles discovery through Phase Ia; Genentech takes over global clinical development and commercialization. The DUPAC platform is one of DualityBio's four proprietary ADC platforms and is dedicated to payloads with novel mechanisms of action designed to address resistance to existing topoisomerase inhibitor-based ADCs (Trodelvy, Enhertu, Datroway, and successors). The deal is Genentech's second Asia-based ADC alliance in a week and continues the pattern of large pharma buying diverse payload chemistries as ADC-first-line combinations expand.